Revvity, Inc. (RVTY) Income Statement Analysis

See more : Genting Plantations Berhad (2291.KL) Income Statement Analysis – Financial Results

Complete financial analysis of Revvity, Inc. (RVTY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Revvity, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.

You may be interested

BankInvest Globale Obligationer Ansvarlig Udvikling Akk. A (BAIGOAUAA.CO) Income Statement Analysis – Financial Results
Titan Medical Inc. (TMD.TO) Income Statement Analysis – Financial Results
Argosy Minerals Limited (ARYMF) Income Statement Analysis – Financial Results
Eurasia Travel Co., Ltd. (9376.T) Income Statement Analysis – Financial Results
Lotus Horizon Holdings Limited (6063.HK) Income Statement Analysis – Financial Results

Revvity, Inc. (RVTY)

Industry: Medical - Diagnostics & Research

Sector: Healthcare

Website: https://www.perkinelmer.com

About Revvity, Inc.

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Revenue	2.75B	3.31B	5.07B	3.78B	2.88B	2.78B	2.26B	2.12B	2.26B	2.24B	2.17B	2.12B	1.92B	1.70B	1.81B	1.94B	1.79B	1.55B	1.47B	1.69B	1.54B	1.50B	1.33B	1.70B	1.36B	1.41B	1.46B	1.43B	1.42B	1.33B	2.70B	2.79B	2.69B	2.47B	1.65B	1.41B	1.24B	1.15B	1.16B
Cost of Revenue	1.21B	1.32B	2.22B	1.67B	1.49B	1.44B	1.18B	1.10B	1.24B	1.23B	1.19B	1.15B	1.07B	945.72M	1.03B	1.11B	1.06B	918.29M	859.30M	1.01B	906.27M	904.10M	721.73M	918.43M	787.30M	991.30M	1.04B	1.01B	1.01B	957.80M	2.30B	2.39B	2.31B	2.14B	1.35B	1.11B	984.00M	935.30M	927.90M
Gross Profit	1.54B	1.99B	2.85B	2.11B	1.40B	1.34B	1.07B	1.01B	1.02B	1.00B	976.97M	963.21M	850.58M	758.63M	779.79M	830.11M	724.74M	628.07M	614.54M	680.55M	628.95M	600.88M	608.33M	776.84M	575.80M	416.60M	420.70M	419.50M	407.00M	374.80M	393.20M	401.50M	382.00M	333.50M	303.80M	292.00M	251.90M	209.80M	227.20M
Gross Profit Ratio	55.98%	60.08%	56.27%	55.78%	48.41%	48.27%	47.54%	47.90%	45.28%	44.90%	45.10%	45.54%	44.27%	44.51%	43.03%	42.84%	40.55%	40.62%	41.70%	40.34%	40.97%	39.93%	45.74%	45.82%	42.24%	29.59%	28.80%	29.39%	28.67%	28.13%	14.57%	14.40%	14.21%	13.48%	18.41%	20.76%	20.38%	18.32%	19.67%
Research & Development	216.58M	221.62M	274.97M	205.39M	189.34M	194.00M	139.40M	124.28M	125.93M	121.14M	133.02M	132.64M	115.82M	95.41M	107.25M	108.06M	111.62M	99.72M	87.37M	87.05M	83.15M	86.45M	81.32M	86.12M	71.20M	46.00M	44.90M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	1.02B	1.03B	1.23B	917.89M	815.32M	811.91M	616.17M	600.89M	598.85M	659.34M	585.85M	632.73M	628.60M	490.66M	504.70M	522.88M	444.41M	376.85M	365.46M	387.54M	386.40M	431.30M	411.15M	418.98M	327.10M	226.30M	243.40M	290.90M	284.90M	278.20M	234.60M	242.00M	223.10M	195.90M	179.90M	169.30M	151.40M	133.20M	130.10M
Other Expenses	0.00	25.26M	36.41M	-23.52M	-27.69M	-13.21M	33.59M	-3.73M	-4.80M	-5.54M	-14.84M	-2.92M	-3.88M	-2.14M	0.00	0.00	-15.35M	1.74M	-1.50M	28.89M	25.67M	23.11M	0.00	87.72M	66.10M	50.40M	44.60M	40.90M	39.40M	36.80M	37.80M	36.30M	33.70M	29.90M	25.50M	24.60M	21.20M	16.40M	15.10M
Operating Expenses	1.24B	1.25B	1.50B	1.12B	1.00B	1.01B	755.57M	725.16M	724.78M	780.48M	718.87M	765.37M	744.42M	586.07M	611.95M	630.95M	540.69M	478.31M	451.33M	503.48M	495.22M	540.87M	492.46M	592.81M	464.40M	322.70M	332.90M	331.80M	324.30M	315.00M	272.40M	278.30M	256.80M	225.80M	205.40M	193.90M	172.60M	149.60M	145.20M
Cost & Expenses	2.45B	2.57B	3.72B	2.80B	2.49B	2.44B	1.94B	1.83B	1.96B	2.01B	1.91B	1.92B	1.82B	1.53B	1.64B	1.74B	1.60B	1.40B	1.31B	1.51B	1.40B	1.44B	1.21B	1.51B	1.25B	1.31B	1.37B	1.34B	1.34B	1.27B	2.58B	2.67B	2.56B	2.37B	1.55B	1.31B	1.16B	1.08B	1.07B
Interest Income	72.13M	3.59M	2.24M	1.01M	1.50M	1.14M	2.57M	702.00K	673.00K	667.00K	650.00K	747.00K	1.88M	832.00K	1.04M	4.02M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	98.81M	103.96M	102.13M	49.71M	63.63M	66.98M	43.94M	41.53M	38.00M	36.27M	49.92M	45.79M	24.78M	15.89M	17.16M	82.14M	41.70M	0.00	0.00	47.71M	105.08M	279.72M	128.31M	74.63M	7.00M	0.00	64.60M	8.90M	0.00	121.80M	12.10M	0.00	900.00K	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	431.77M	427.00M	311.44M	246.51M	214.03M	180.59M	105.00M	99.97M	121.48M	125.26M	154.94M	126.87M	129.26M	108.96M	113.11M	125.10M	103.50M	66.84M	124.38M	89.51M	89.78M	96.11M	84.26M	127.26M	66.10M	50.40M	44.60M	48.20M	36.00M	36.80M	30.50M	31.10M	29.70M	19.90M	15.00M	17.70M	12.20M	16.40M	15.10M
EBITDA	713.56M	1.30B	1.73B	1.20B	609.55M	518.76M	424.63M	405.96M	378.63M	322.61M	331.73M	223.24M	200.06M	267.04M	200.91M	262.65M	264.89M	219.24M	287.59M	266.58M	223.51M	156.13M	200.13M	311.28M	177.50M	82.10M	166.20M	135.90M	118.70M	168.00M	151.30M	154.30M	154.90M	127.60M	113.40M	115.80M	91.50M	57.20M	79.00M
EBITDA Ratio	25.94%	36.19%	34.45%	32.00%	20.09%	18.13%	20.32%	18.21%	18.02%	15.02%	17.19%	15.25%	11.40%	15.41%	14.39%	16.42%	15.20%	14.24%	24.34%	15.80%	17.83%	14.58%	21.19%	18.36%	17.89%	5.83%	11.38%	9.52%	8.36%	12.61%	5.61%	5.53%	5.76%	5.16%	6.87%	8.23%	7.40%	5.00%	6.84%
Operating Income	300.56M	742.70M	1.33B	978.58M	361.97M	323.88M	304.80M	283.07M	286.13M	210.74M	217.44M	195.66M	89.70M	153.60M	147.61M	192.97M	168.17M	153.40M	234.29M	177.07M	183.91M	123.37M	197.58M	184.03M	104.40M	31.70M	121.60M	87.70M	82.70M	131.20M	120.80M	123.20M	125.20M	107.70M	98.40M	98.10M	79.30M	40.80M	63.90M
Operating Income Ratio	10.93%	22.43%	26.29%	25.87%	12.55%	11.66%	13.50%	13.38%	12.65%	9.42%	10.04%	9.25%	4.67%	9.01%	8.15%	9.96%	9.41%	9.92%	15.90%	10.49%	11.98%	8.20%	14.86%	10.86%	7.66%	2.25%	8.32%	6.14%	5.83%	9.85%	4.48%	4.42%	4.66%	4.35%	5.96%	6.98%	6.42%	3.56%	5.53%
Total Other Income/Expenses	-117.59M	-90.86M	-54.88M	39.09M	-124.83M	-66.20M	1.10M	-50.51M	-42.12M	4.60M	-53.76M	-140.50M	-26.77M	-10.78M	-15.79M	-45.61M	-16.88M	-2.67M	-74.29M	-38.33M	-56.39M	-32.87M	-163.43M	-39.54M	-66.50M	124.30M	-35.80M	-7.30M	3.40M	-76.90M	1.10M	-2.10M	-4.90M	-500.00K	1.40M	-700.00K	1.70M	31.50M	24.70M
Income Before Tax	182.98M	651.84M	1.28B	906.36M	237.14M	257.68M	296.72M	244.07M	244.02M	169.60M	153.33M	50.59M	62.93M	161.98M	130.68M	147.36M	151.29M	150.74M	66.66M	136.75M	80.88M	-8.55M	34.15M	144.49M	44.90M	156.00M	54.00M	80.40M	86.10M	-17.10M	121.90M	121.10M	120.30M	107.20M	99.80M	97.40M	81.00M	72.30M	88.60M
Income Before Tax Ratio	6.65%	19.68%	25.26%	23.96%	8.22%	9.28%	13.15%	11.54%	10.79%	7.58%	7.08%	2.39%	3.28%	9.50%	7.21%	7.61%	8.46%	9.75%	4.52%	8.10%	5.27%	-0.57%	2.57%	8.52%	3.29%	11.08%	3.70%	5.63%	6.07%	-1.28%	4.52%	4.34%	4.47%	4.33%	6.05%	6.93%	6.55%	6.31%	7.67%
Income Tax Expense	3.47M	129.16M	347.60M	178.27M	9.39M	20.21M	139.83M	28.36M	31.33M	8.44M	-12.19M	-17.85M	62.75M	26.06M	37.93M	21.22M	17.46M	32.41M	128.00K	38.50M	25.87M	-4.42M	34.77M	58.42M	16.50M	54.00M	23.40M	25.90M	31.80M	15.00M	42.30M	33.30M	39.10M	33.20M	29.90M	28.70M	25.50M	27.40M	32.90M
Net Income	693.09M	569.18M	943.16M	727.89M	227.56M	237.93M	156.89M	234.30M	212.43M	157.78M	167.21M	69.94M	174.00K	135.92M	85.60M	126.41M	131.69M	119.58M	66.53M	96.04M	52.96M	-4.14M	-620.00K	90.52M	28.40M	102.00M	33.70M	60.20M	54.30M	-32.10M	79.60M	87.80M	81.20M	74.00M	69.90M	68.70M	55.50M	44.90M	55.70M
Net Income Ratio	25.20%	17.19%	18.61%	19.24%	7.89%	8.56%	6.95%	11.08%	9.39%	7.05%	7.72%	3.31%	0.01%	7.98%	4.72%	6.52%	7.37%	7.73%	4.51%	5.69%	3.45%	-0.27%	-0.05%	5.34%	2.08%	7.24%	2.31%	4.22%	3.83%	-2.41%	2.95%	3.15%	3.02%	2.99%	4.24%	4.89%	4.49%	3.92%	4.82%
EPS	5.56	4.51	8.12	6.53	2.05	2.15	1.43	2.14	1.89	1.40	1.49	0.61	0.00	1.16	0.74	1.07	1.11	0.96	0.51	0.75	0.42	-0.03	-0.01	0.92	0.31	1.13	0.37	0.64	0.53	-0.29	0.71	0.78	0.73	0.65	0.60	0.57	0.50	0.42	0.52
EPS Diluted	5.55	4.50	8.08	6.49	2.04	2.13	1.42	2.12	1.87	1.39	1.47	0.61	0.00	1.15	0.73	1.07	1.09	0.95	0.51	0.74	0.41	-0.03	-0.01	0.89	0.31	1.11	0.37	0.64	0.51	-0.29	0.71	0.78	0.73	0.65	0.60	0.57	0.50	0.42	0.52
Weighted Avg Shares Out	124.70M	126.16M	116.17M	111.51M	110.83M	110.56M	109.86M	109.48M	112.51M	112.59M	112.25M	113.73M	112.98M	117.11M	116.25M	117.66M	118.64M	124.57M	129.52M	128.06M	126.09M	125.57M	104.56M	98.39M	91.30M	90.27M	91.08M	94.80M	103.03M	112.00M	112.57M	112.56M	111.23M	113.85M	116.50M	119.48M	111.00M	108.19M	107.12M
Weighted Avg Shares Out (Dil)	124.81M	126.43M	116.67M	112.09M	111.50M	111.53M	110.86M	110.31M	113.32M	113.74M	113.50M	114.86M	113.86M	117.98M	116.59M	118.69M	120.81M	125.88M	131.43M	129.79M	129.17M	125.57M	107.83M	101.71M	91.30M	91.89M	91.08M	94.80M	105.98M	112.00M	112.57M	112.56M	111.23M	113.85M	116.50M	119.48M	111.00M	108.19M	107.12M

Earnings Preview: Revvity (RVTY) Q3 Earnings Expected to Decline

October 28, 2024zacks.com

Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revvity Board Declares Quarterly Dividend

October 24, 2024businesswire.com

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 7, 2025 to all shareholders of record at the close...

Revvity Shares Decline Despite Launch of Transcribe AI Solution

October 23, 2024zacks.com

RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors.

Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report

October 22, 2024businesswire.com

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today unveils its annual Impact Report, a declaration of the Company's sustainability, social and governance strategy, initiatives and performance. The report showcases Revvity's continued evolution and strengthened commitments to creating a lasting, positive impact...

1 2 3 4 5 6 7 8 9 10

Source: https://incomestatements.info
Category: Stock Reports

Revvity, Inc. (RVTY) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories